Finance / Per-Study Forecast
Study Drill · Type 2 Diabetes
ENDO-156 / revenue book
● 27 active subjects · 156 visits remaining
Recognized YTD
$150.6K
actual
Remaining Contract
$170.5K
under SOW
$ / Subject
$11,900
full course
Q4 Forecast
$321.3K
this quarter
Subject Revenue Waterfall
recognized · remainingTotal contract value · 27 subjects$321,084
Subjects · 27
| Subject | Visits | Recog. | Status |
|---|---|---|---|
| 1000 | 3/12 | $2,973 | Invoiced |
| 1001 | 4/12 | $3,964 | Invoiced |
| 1002 | 5/12 | $4,955 | Invoiced |
| 1003 | 6/12 | $5,946 | Pending |
| 1004 | 7/12 | $6,937 | Invoiced |
| 1005 | 7/12 | $6,937 | Hold |
| 1006 | 8/12 | $7,928 | Invoiced |
| 1007 | 3/12 | $2,973 | Invoiced |
| 1008 | 4/12 | $3,964 | Invoiced |
| 1009 | 5/12 | $4,955 | Invoiced |
| 1010 | 6/12 | $5,946 | Pending |
| 1011 | 7/12 | $6,937 | Invoiced |
| 1012 | 7/12 | $6,937 | Hold |
| 1013 | 8/12 | $7,928 | Invoiced |
| 1014 | 3/12 | $2,973 | Invoiced |
| 1015 | 4/12 | $3,964 | Invoiced |
| 1016 | 5/12 | $4,955 | Invoiced |
| 1017 | 6/12 | $5,946 | Pending |
| 1018 | 7/12 | $6,937 | Invoiced |
| 1019 | 7/12 | $6,937 | Hold |
| 1020 | 8/12 | $7,928 | Invoiced |
| 1021 | 3/12 | $2,973 | Invoiced |
| 1022 | 4/12 | $3,964 | Invoiced |
| 1023 | 5/12 | $4,955 | Invoiced |
| 1024 | 6/12 | $5,946 | Pending |
| 1025 | 7/12 | $6,937 | Invoiced |
| 1026 | 7/12 | $6,937 | Hold |
Visit Schedule · next 12 weeks · billable revenue
AR Aging · this study
0-30 days$27,113
9 invoices
31-60 days$13,556
5 invoices
61-90 days$6,025
3 invoices
90+ days$3,012
1 invoices